LT3645002T - Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais - Google Patents

Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais

Info

Publication number
LT3645002T
LT3645002T LTEPPCT/US2018/040181T LTUS2018040181T LT3645002T LT 3645002 T LT3645002 T LT 3645002T LT US2018040181 T LTUS2018040181 T LT US2018040181T LT 3645002 T LT3645002 T LT 3645002T
Authority
LT
Lithuania
Prior art keywords
sarcomer
activators
cardiac
heart failure
treating heart
Prior art date
Application number
LTEPPCT/US2018/040181T
Other languages
English (en)
Lithuanian (lt)
Inventor
Narimon HONARPOUR
Fady Malik
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of LT3645002T publication Critical patent/LT3645002T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2018/040181T 2017-06-30 2018-06-29 Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais LT3645002T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
LT3645002T true LT3645002T (lt) 2025-02-10

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/040181T LT3645002T (lt) 2017-06-30 2018-06-29 Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais

Country Status (22)

Country Link
US (4) US11576910B2 (cg-RX-API-DMAC10.html)
EP (2) EP4512470A3 (cg-RX-API-DMAC10.html)
JP (3) JP2020526483A (cg-RX-API-DMAC10.html)
CN (1) CN110996953A (cg-RX-API-DMAC10.html)
AU (2) AU2018290983B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019028046A2 (cg-RX-API-DMAC10.html)
CA (1) CA3068588A1 (cg-RX-API-DMAC10.html)
DK (1) DK3645002T3 (cg-RX-API-DMAC10.html)
ES (1) ES3008457T3 (cg-RX-API-DMAC10.html)
FI (1) FI3645002T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241729T1 (cg-RX-API-DMAC10.html)
HU (1) HUE069805T2 (cg-RX-API-DMAC10.html)
LT (1) LT3645002T (cg-RX-API-DMAC10.html)
MA (1) MA49508B1 (cg-RX-API-DMAC10.html)
MD (1) MD3645002T2 (cg-RX-API-DMAC10.html)
MX (2) MX2020000190A (cg-RX-API-DMAC10.html)
PL (1) PL3645002T3 (cg-RX-API-DMAC10.html)
PT (1) PT3645002T (cg-RX-API-DMAC10.html)
RS (1) RS66581B1 (cg-RX-API-DMAC10.html)
SI (1) SI3645002T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500067T1 (cg-RX-API-DMAC10.html)
WO (1) WO2019006235A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
WO2021163172A1 (en) * 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
JP7832128B2 (ja) * 2020-06-15 2026-03-17 マイオカーディア,インク 心房機能不全の治療
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
IL302850A (en) * 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス, インコーポレイテッド キナゾリンジオン化合物およびその使用
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法
AU2018214629A1 (en) 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
CN112118846B (zh) 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CA3157629A1 (en) 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
WO2021163172A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
MD3645002T2 (ro) 2025-04-30
CN110996953A (zh) 2020-04-10
MA49508B1 (fr) 2024-12-31
US11931358B2 (en) 2024-03-19
CA3068588A1 (en) 2019-01-03
HUE069805T2 (hu) 2025-04-28
FI3645002T3 (fi) 2025-01-29
US20230149394A1 (en) 2023-05-18
MX2020000190A (es) 2020-07-22
MA49508A (fr) 2020-05-06
US20230355615A1 (en) 2023-11-09
RS66581B1 (sr) 2025-04-30
PT3645002T (pt) 2025-01-24
EP3645002B1 (en) 2024-10-30
ES3008457T3 (en) 2025-03-24
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
DK3645002T3 (da) 2024-12-16
US11576910B2 (en) 2023-02-14
SMT202500067T1 (it) 2025-03-12
EP3645002A1 (en) 2020-05-06
EP4512470A3 (en) 2025-04-23
JP2020526483A (ja) 2020-08-31
AU2024200991A1 (en) 2024-03-07
SI3645002T1 (sl) 2025-03-31
US12295952B2 (en) 2025-05-13
US20250255862A1 (en) 2025-08-14
EP4512470A2 (en) 2025-02-26
US20200155547A1 (en) 2020-05-21
WO2019006235A1 (en) 2019-01-03
AU2018290983B2 (en) 2023-11-23
MX2022015115A (es) 2023-01-18
AU2024200991B2 (en) 2025-04-10
JP2025165979A (ja) 2025-11-05
HRP20241729T1 (hr) 2025-03-14
PL3645002T3 (pl) 2025-03-24
JP2023088944A (ja) 2023-06-27

Similar Documents

Publication Publication Date Title
PT3645002T (pt) Métodos de tratamento da insuficiência cardíaca com ativadores do sarcómero cardíaco
IL253954A0 (en) Implantable devices and related methods for heart failure monitoring
IL271059A (en) Determination of cardiac parameters for modulation of blood pump support
IL272300A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
EP3157468C0 (en) SURGICAL HEART VALVES IDENTIFIABLE AFTER IMPLANTATION
EP4230133C0 (en) CONTROLLED AND PRECISE TREATMENT OF CARDIAC TISSUES
PL3265053T3 (pl) Sposoby leczenia skóry
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
EP3359085C0 (en) CONTROLLED AND PRECISE TREATMENT OF CARDIAC TISSUES
EP3298235A4 (en) PREDICTION OF FORMATION AND STRATIGRAPHIC LAYERS DURING DRILLING
IL247088A0 (en) Matching and tracking time sequences of heart activation
LT3359037T (lt) Informacios apie širdies būklę gavimo būdas ir aparatas
PL3134526T3 (pl) LncRNA do terapii i diagnozowania przerostu serca
EP3724219A4 (en) TREATMENT OF FIBROSIS BY GENETICALLY MODIFIED MACROPHAGES
EP3503904C0 (en) ASCAROSIDE TREATMENT OF EOSINOPHIL ESOPHAGITIS
LT3728410T (lt) Lignoceliuliozės biomasės apdorojimo būdas
DK4212152T3 (da) Sacubitril-valsartan-doseringsregime til behandling af kronisk systolisk hjertesvigt
EP3424557A4 (en) INTRAKARDIAL DEFIBRILLATION CATHETER
EP3436569A4 (en) ADVANCED DIRECT CARDIAL PROGRAMMING
ZA202002292B (en) Methods of treating heart failure with preserved ejection fraction
IL254825A0 (en) Methods of treatment with taselisib
PL3661510T3 (pl) Sposoby leczenia zmian zachowania
IL275273A (en) An improved compound for the treatment of heart failure
EP3256137A4 (en) Method of treating heart failure
EP3223903C0 (en) CARDIAC PACING DETECTION AND REGULATION